Oryzon Genomics (BME: ORY)

Last close As at 27/03/2024

EUR1.71

0.00 (0.00%)

Market capitalisation

EUR107m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset Vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Update

Oryzon Genomics — Approaching a period of inflection

Healthcare | Update

Oryzon Genomics — PORTICO update with planned FDA EoP2

Healthcare | edison tv

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (8.3) (16.0) (19.1)
Relative (15.4) (22.7) (35.3)
52 week high/low €2.4/€1.6

Financials

ORY FY23 results announcement covered an eventful period for the company’s pipeline, capped by the release of top-line data from the Phase IIb PORTICO trial for lead CNS asset vafidemstat. With the focus squarely on the planned end of Phase II (EoP2) meeting with the FDA and anticipated clinical updates on the remaining programmes, we see FY24 as a crucial period for the company, with multiple inflection points. Other key upcoming milestones include results from the FRIDA trial (iadademstat in FLT3+ r/r acute myeloid leukaemia; expected in Q224) and a clinical timeline update from the EVOLUTION trial (vafidemstat in schizophrenia; expected in 2024). Based on the current status of the company’s programmes and improved visibility, we have adjusted our market strategy, launch timelines and valuation across the company’s pipeline, leading to a valuation reset to €11.8/share (€15.1/share previously).

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.3) (7.49) N/A N/A
2023A 14.2 (4.4) (6.0) (5.65) N/A N/A
2024E 12.9 (3.1) (4.2) (2.71) N/A N/A
2025E 33.7 16.9 15.5 29.18 5.9 5.8

Flash note

Healthcare

Oryzon Genomics — Promising PORTICO interim results

Oryzon-Genomics_resized

Update

Healthcare

Oryzon Genomics — Catalysts on the horizon in FY23

Flash note

Healthcare

Oryzon Genomics — Progress in oncology and CNS in FY22

Flash note

Healthcare

Oryzon Genomics — Encouraging safety data in PORTICO

Flash note

Healthcare

Oryzon Genomics — Costs up but company remains well funded

testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — CRADA win to provide a halo effect

Flash note

Healthcare

Oryzon Genomics — FRIDA funding and orphan drug designation

edison tv

Healthcare

Oryzon– Edison Open House interview

testalize-me-0jE8ynV4mis-unsplash

Update

Healthcare

Oryzon Genomics — First vafidemstat efficacy data

Update

Healthcare

Oryzon Genomics — A year of data readouts

edison tv

Healthcare

Executive interview – Oryzon

Outlook

Healthcare

Oryzon Genomics — Awaiting for eventful 2019

Update

Healthcare

Oryzon Genomics — ORY-2001 and ORY-3001 next in focus

Outlook

Healthcare

Oryzon Genomics — Maturing epigenetics portfolio

edison tv

Healthcare

Executive Interview – Oryzon

Update

Healthcare

Oryzon Genomics — New data further back MS indication

testalize-me-0jE8ynV4mis-unsplash

Update

Healthcare

Oryzon Genomics — Update 9 December 2016

Update

Healthcare

Oryzon Genomics — Update 16 November 2016

research

Healthcare

Oryzon Genomics — Update 3 November 2016

Update

Healthcare

Oryzon Genomics — Update 8 August 2016

Update

Healthcare

Oryzon Genomics — Update 20 May 2016

testalize-me-0jE8ynV4mis-unsplash

Initiation

Healthcare

Oryzon Genomics — Update 9 March 2016

QuickView

Healthcare

Oryzon Genomics — Update 5 January 2016